Rigel Pharmaceuticals to Present R289 Data at ASH Annual Meeting 2025

Rigel Pharmaceuticals Prepares for ASH Annual Meeting Presentation on R289

Rigel Pharmaceuticals, Inc. is poised to showcase its advancements in hematologic disorders at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, scheduled for December 6-9, 2025. The biotechnology firm announces that it will present updated data from its ongoing Phase 1b study of R289, a dual IRAK1/4 inhibitor, which aims to address the significant unmet needs in treating relapsed or refractory lower-risk myelodysplastic syndrome (MDS). The meeting will provide an important platform for Rigel to highlight its commitment to developing innovative therapies in this challenging therapeutic area.

The Phase 1b study of R289 focuses on a particularly vulnerable patient population, with 33 participants enrolled as of mid-July 2025. Notably, the median age of these patients is 75, and many have undergone multiple prior therapies, indicating a high level of treatment resistance. Dr. Lisa Rojkjaer, Rigel's chief medical officer, expresses enthusiasm regarding the presentation, emphasizing the importance of exploring new treatment avenues for patients burdened by high transfusion needs. The presentation, titled "An Update of Safety and Efficacy Results from a Phase 1b Study of R289," will be delivered by Dr. Guillermo Garcia-Manero, who will discuss the preliminary safety and efficacy findings of this promising candidate.

In addition to R289, Rigel plans to showcase four poster presentations on REZLIDHIA® (olutasidenib), another key product in its hematology portfolio, aimed at addressing relapsed or refractory mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML). These presentations at ASH signify a strategic effort by Rigel to reinforce its position in the hematology and oncology fields, ultimately striving to improve treatment outcomes for patients facing challenging hematologic malignancies. As the company prepares for these important discussions, the focus remains on advancing its therapeutic pipeline and addressing the critical needs of patients with hematologic disorders.

In addition to the ASH meeting preparations, Rigel Pharmaceuticals is set to announce its quarterly earnings on November 4, 2025. Analysts are closely watching the company's performance metrics, particularly in relation to its ongoing clinical trials and product candidates focused on rare diseases. With expectations of a revenue increase and strategic partnerships enhancing its research capabilities, stakeholders remain optimistic about the company's financial outlook and its impact on future growth in the biotechnology sector.